Bluebird bio inks first Medicaid coverage agreement for sickle cell gene therapy, signing on with Michigan

Bluebird bio has secured its first Medicaid outcomes-based agreement for its sickle cell disease gene therapy Lyfgenia (lovo-cel), signing on with the state of Michigan.